Physicians' Academy for Cardiovascular Education

Covid-19

Overview of recent news and publications on COVID-19 and cardiovascular disease

Expert Position Paper on conducting HF clinical trials in the COVID-19 era

News - June 17, 2020

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has published an expert consensus position paper on conducting clinical trials in HF during and after the COVID-19 pandemic.

Health professionals report decrease in STEMI admissions since COVID-19 outbreak

Literature - June 15, 2020 - Pessoa-Amorim G et al., - Eur Heart J Qual Care Clin Outcomes. 2020.

A survey conducted by the ESC among cardiologists and CV nurses revealed that 78.8% of responders perceived a decrease in STEMI admissions since the beginning of the COVID-19 outbreak.

Prevention and management of CVD in diabetes patients in the COVID-19 era

News - June 2, 2020

Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.

Use of in-hospital anticoagulation and mortality in hospitalized COVID-19 patients

Literature - May 27, 2020 - Paranjpe I, et al. - J Am Coll Cardiol 2020

Survival was examined in a cohort of hospitalized COVID-19 patients in New York City, who were divided in those who received anticoagulation during hospital stay and those who did not.

High incidence of acute kidney injury in hospitalized patients with COVID-19

Literature - May 26, 2020 - Hirsch JS et al., - Kidney Int. 2020.

This study showed that 36.3% of patients hospitalized with COVID-19 developed acute kidney injury during hospitalization.

Three studies show no harm of ARBs/ACEi in COVID-19 patients

News - May 26, 2020

Recently, three papers were published in the N Engl J Med on the effect of ACE inhibitors and ARBs in patients with COVID-19. All three studies showed no evidence that ACE inhibitors or ARBs affect the risk of COVID-19.

Practical recommendations for management of diabetes during COVID-19 pandemic

News - May 19, 2020

A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.

Coagulopathy in patients with COVID-19

Literature - May 19, 2020 - Levi M et al., - Lancet Haematol. 2020.

This comment article describes characteristics of coagulopathy in patients with COVID-19 and discusses recommendations for the therapeutic management of COVID-19-associated coagulopathy.

More out-of-hospital cardiac arrests during the COVID-19 outbreak in Lombardy, Italy compared to 2019

Literature - May 8, 2020 - Baldi E, et al. - N Engl J Med 2020

In a letter to the editor, Baldi and colleagues describe a study on the incidence of out-of-hospital cardiac arrest in 4 provinces in Lombardy, Italy, during the initial outbreak of COVID-19.

Increase in out-of-hospital cardiac arrest during the COVID-19 outbreak in Lombardy, Italy

3' education - May 8, 2020 - Enrico Baldi, MD
There was a 58% increase in out-of-hospital cardiac arrest during the inital phase of the COVID-19 outbreak in the Lombardia region in Italy compared to the same period in 2019. Watch a video on the study by Baldi and colleagues.

Out-of-hospital cardiac arrest during the inital phase of the COVID-19 outbreak was substantially increased in the Lombardia region in Italy compared to the same period in 2019. Baldi briefly presents the details and outcomes of a study.

Venous thromboembolism in COVID-19 patients

5' education - May 6, 2020 - Prof. Saskia Middeldorp
COVID-19 can lead to systemic coagulation activation and thrombotic complications. Prof. Middeldorp describes the results of a study investigating the incidence of VTE in hospitalized COVID-19 patients.

COVID-19 can lead to systemic coagulation activation and thrombotic complications. Prof. Middeldorp describes the results of a study investigating the incidence of VTE in hospitalized COVID-19 patients.

Trial started with SGLT2i in COVID-19

News - May 4, 2020
A randomized, phase 3 trial, called DARE-19, evaluates the effect of dapagliflozin on disease progression, clinical complications and mortality in patients hospitalized with COVID-19, who also have CV, metabolic or kidney risk factor.

A randomized, phase 3 trial, called DARE-19, evaluates the effect of dapagliflozin on disease progression, clinical complications and mortality in patients hospitalized with COVID-19, who also have CV, metabolic or kidney risk factor.

Covid-19